GlobeNewswire Inc | Sep 16, 2020 04:30PM EDT

September 16, 2020

LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 8585556#

USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53International Dial-In Number: +1 (409) 350-3501 United-Kingdom: +44 2031070289

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/ypvwj59i

An archived replay of the call will be available for 7 days by dialing + 1855859 2056, Conference ID: 8585556#.

An archive of the webcast will be available on ERYTECHs website, under the Investors section atinvestors.erytech.com

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECHs primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Companys lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site inLyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market inthe United States(ticker: ERYP) and on theEuronext regulated market inParis(ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CACHealthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS

LifeSci Advisors, LLC NewCapERYTECH Corey Davis, Ph.D. Mathilde Bohin / Investor Relations Louis-Victor New York, New York DelouvrierEric Soyer Investor RelationsCFO & COO Nicolas Merigeau Media relations +1 (212) 915 -2577+33 4 78 74 44 38 cdavis@lifesciadvisors.com +33 1 44 71 94 94investors@erytech.com erytech@newcap.eu

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/5ab80fe6-3304-4888-9100-b1ccd3552697